Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresType 2 diabetes (T2D) is associated with increased risk of myocardial infarction (MI). In the LEADER trial (NCT01179048), liraglutide reduced the risk of a composite cardiovascular (CV) outcome (time to the first occurrence of CV death, non-fatal MI, or non-fatal stroke) versus placebo, both in addition to standard care.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
